The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult patients who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-based ...

Third-line treatment with panitumumab alone or irinotecan plus cetuximab is reserved to those patients with KRAS wild-type tumors previously untreated with the anti-EGFR antibody. Whenever the ...